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This study at the Logan Hospital, Australia, compared the outcome of induction of labour (IOL) in nulliparous women following
replacement of Cervidil with Prostin. Eighty-two nulliparous women were identiﬁed for this retrospective cohort study over a
periodofthreemonthsoneithersideofthechangedpractice.Forty-fourwomenreceivedProstinand38receivedCervidil.Baseline
characteristics were similar amongst the groups including maternal age, mean gestational age, and modiﬁed Bishop’s score at the
commencement of IOL. The incidence of amniotomy, oxytocin augmentation of labour, and rate of epidural use did not diﬀer
signiﬁcantly between the groups. The mean time to delivery (vaginally or abdominally) showed a signiﬁcant diﬀerence, with
women receiving Prostin delivering earlier than those having Cervidil (P = 0.018). Women receiving Prostin were more likely to
have assisted vaginal delivery compared to the Cervidil group (P = 0.04).
1.Introduction
Induction of labour (IOL) is one of the commonest inter-
vention in obstetrics. It is estimated that in the developed
world, at least 19.8% of all labours are induced [1]. Vaginal
prostaglandin E2 has been shown to be eﬃcacious to prepare
the cervix [2] for IOL. Various preparations of prostaglandin
are available diﬀering in their eﬀectiveness, side eﬀects [3],
and price [4]. The preparation most commonly used for
IOL is the shorter acting Dinoprostone vaginal gel (Prostin).
Recently longer-acting Dinoprostone preparations (Cervidil
and Propess) with retrieval system have become available
which have been successfully used for IOL. Nevertheless,
some studies [4] show that longer-acting preparations do
not reduce time to delivery or improve any birth outcome
compared to the shorter acting gel which is also considered
more cost eﬀective [5]. It has been noted [3] that more than
one dose of the long acting preparation is needed to achieve
amniotomy compared to the shorter acting one. The only
consistent beneﬁt seems to be the lesser number of vaginal
examinations with the long acting preparations.
A potential risk of IOL is failure of this intervention
resulting in delivery by Caesarean section (CS) [6]. Recent
ﬁndings [1] show that following IOL the emergency CS rate
may be as high as 22%. Others [7] have noted that IOL
in nulliparous women at term, with or without medical or
obstetric complications, signiﬁcantly increases the chance
of CS. CS rates in primiparous women are a variable life-
adjusted (VLAD) clinical indicator in Queensland, Australia.
VLAD is a statistical control chart used by the Queensland
Health to better monitor treatment outcomes across the state
[8]. The VLAD tool records patient outcomes for any clinical
indicator at a particular facility identifying variation against
the state averages. It is believed that any variation may reﬂect
shift in practice or treatment quality.
Logan Hospital in Queensland has been using Cervidil
for IOL in nulliparous women for three years till June 2010.
There was a change in practice for IOL from July 2010
when Cervidil was replaced with Prostin. The purpose of this
retrospective cohort study was to compare the outcome of
IOL three months after the change in practice with regards
to the time interval between the initiation of the induction
process and the birth of the baby and impact on the mode of
delivery.
2. Methods
Logan Hospital is a secondary level general hospital in
Queensland,AustraliawithintheMetroSouthHealthService2 The Scientiﬁc World Journal
District with an annual delivery rate of 3500. It serves
a population of around 300,000 and is one of the most
multicultural districts in Australia representing some 185
ethnicities. The population is young with a median age of
33 years, and 30% of the population is aged between 25 and
44 years [9].
The women for this retrospective cohort study were
identiﬁed from the IOL database which is an in-hospital
electronic record system. The data was obtained from the
hospital electronic patient record system (ERIC) which
archives every patient record entry and obviates the need for
any hard copy. Information was collected on the outcome of
IOL in nulliparous women induced in the last three months
of Cervidil use (May–July, 2010) and the ﬁrst three months
after the change to Prostin (August–October, 2010). This
time frame was speciﬁcally chosen to minimize the inﬂuence
of operator skill as doctors who work on the birth suite, do
so for a period of twelve weeks at a stretch, working alternate
weeks to comply with the directive on hours worked. The
departmental protocol till 31st of July 2010 for IOL in
a nulliparous woman with a singleton foetus in cephalic
presentation regardless of the gestation is described below.
Planned IOL was to commence at 1400hrs. An initial
vaginal examination was done to determine the modiﬁed
Bishop’s score [10]. If the score was greater than 6 then
the woman was to have amniotomy next morning at
0600 followed by augmentation with oxytocin infusion if
necessary. If the modiﬁed Bishop’s score was less than 7,
then labour was induced by placing Cervidil (retrievable
controlled release 10mg Dinoprostone pessary releasing
0.3mgDinoprostone/hour)intotheposteriorvaginalfornix.
Electronic foetal monitoring was done for an hour after
insertion of Cervidil. The next assessment would be at 0600
the following morning or earlier if there was any suggestion
of active labour. If cervix was unfavourable for amniotomy
then consultant advice was sought regarding further pros-
taglandin gel.
This practice was changed from 1st of August 2010 when
Cervidil was replaced with Prostin. A 2mg dose was placed
into the posterior fornix at 1400 hours followed by electronic
foetal monitoring for 1 hour. A reassessment was done six
hours later, and a further 1mg intravaginal gel was inserted
if the modiﬁed Bishop’s score was less than 7. Amniotomy
wasdoneifthisscorewasgreaterthan6.Iftheseconddoseof
intravaginal gel was administered then, the next examination
was at 0600 the following morning to consider amniotomy
or the need for a further third 1mg dose of intravaginal
gel. Regardless of the change in practice, failed IOL was
deﬁned as inability of the agent to dilate the cervix to enable
amniotomy, or failure of the cervix to dilate beyond 4cm
despite at least 10 hours of a titrated oxytocin infusion.
Though this study was based on an audit of a change
in departmental practice, an ethical approval was obtained
from the local Human Research Ethics Committee of the
Metro South Health Service District of Queensland Health
of Queensland Government, Australia.
Data was entered on a Microsoft Excel spreadsheet.
Statistical analysis was done using Analyse-it (version 2.20)
statistics software for Microsoft Excel. The groups were
Table 1: Baseline characteristics of the women in the Prostin and
Cervidil induction agent groups.
Characteristic Prostin
(N = 44)
Cervidil
(N = 38
§) P
Age (yrs) 24.5 25.2 0.465
Gestation (weeks) 40.2 40.2 0.978
BMI
Bishops score
(median) 2 2 1.000
Primary Indication Number (%)
Cholestasis 1(2.3) 1(2.6) 1.00
Growth restriction 4(9.1) 1(2.6) 0.458
GDM 6(13.6) 5(13.2) 1.000
Hypertension 7(15.9) 8(21.1) 0.751
After term 24(54.5) 22(57.9) 0.936
Social 1(2.3) 1(2.6) 1.000
Isoimmunisation 1(2.3) 0(0) —
§1 case excluded due to induction being cancelled after commencement.
compared using contingency table and chi-square analysis
for categorical and binary values. Continuous variables were
analysed by a t-test. Two-sided P values are reported for all
tests. Values 0.05 or less were regarded as signiﬁcant.
3. Results
There were 83 women who were eligible for inclusion, 44
in the Prostin group, and 39 in the Cervidil group. One
case was excluded from the Cervidil group (n = 38) as the
IOL was commenced with Cervidil, postponed, and then
recommenced 3 days later with Prostin making classiﬁcation
impossible.
The baseline characteristics were similar amongst both
groups as shown in Table 1 including maternal age, mean
gestational age at IOL, and the modiﬁed Bishop’s score at
the commencement of IOL. As expected, the commonest
indication for IOL in both groups was prolonged pregnancy
beyond40weeksofgestation.Othercommonindicationsfor
IOL were hypertensive diseases in pregnancy and gestational
diabetes mellitus.
Outcome of IOL in the two groups is detailed in Table 2.
The number of women requiring amniotomy and oxytocin
infusion to cause eﬀective contractions and delivery did not
diﬀer between the two groups. The incidence of epidural
analgesia use during labour did not vary between the two
groups either. Four women were recorded as having a failed
IOL, one in the Prostin group and three in the Cervidil
group (RR 0.29, 95%, CI 0.03–2.65, P = 0.51), but this
diﬀerence was not signiﬁcant. There was no diﬀerence in
the incidence of caesarean section (RR 0.65, 95% CI 0.35–
1.19, P = 0.24) between the Prostin and Cervidil groups.
There was also no statistically signiﬁcant diﬀerence in the
number of women needing an operative delivery (either a
caesarean section or assisted vaginal delivery) between the
twogroups(RR1.12,95%CI0.76–1.66,P = 0.72).However,The Scientiﬁc World Journal 3
Table 2: Maternal outcomes following Induction of labour with Prostin or Cervidil.
Prostin
(N = 44)
Cervidil
(N = 38) RR 95% CI P
Number (%)
Failed induction 1(2.3) 3(7.9) 0.29 0.03–2.65 0.51
Amniotomy 27(61.4) 24(63.2) 0.97 0.69–1.36 1.00
Oxytocin infusion 29(65.9) 24(63.2) 1.04 0.76–1.44 0.98
Epidural analgesia 19(43.2) 18(44.4) 0.91 0.57–1.47 0.87
LSCS 12(27.3) 16(42.1) 0.65 0.35–1.19 0.24
Vaginal delivery 32(72.7) 22(57.9) 1.26 0.91–1.74 0.24
Instrumental Delivery# 14(31.8) 4(10.5) 3.0 1.1–8.4 0.04
NonInstrumental Delivery 18(40.9) 18(47.4) 0.86 0.53–1.41 0.72
LSCS or instrumental Delivery# 26(59.9) 20(68.4) 1.12 0.76–1.66 0.72
Mean time to deliver§(hrs) 21.1 29.6 0.02
LSCS: lower segment caesarean section.
#Vacuum extractor or obstetric forceps used to assist vaginal delivery.
§From application of induction agent until delivery of neonate.
there was a signiﬁcant diﬀerence in the number of women
requiring instrumental delivery, with those receiving Prostin
more likely to need assisted vaginal delivery (RR 3.0, 95%
CI 1.1–8.4, P = 0.04). The mean time to delivery for all
women also showed a signiﬁcant diﬀerence, with women
receiving Prostin delivering earlier on average than those
having Cervidil (21.1 versus 29.6hrs P = 0.018) irrespective
of the mode of delivery.
4. Discussion
IOL is a common obstetric intervention. It is therefore con-
sideredanimportantclinicalindicatorbothbytheAustralian
council of Healthcare standards [11] and Core maternity
indicator project Australia [12]. Moreover, failed induction
of labour results in caesarean section which again is a VLAD
indicator especially in nulliparous women. Hence, judicious
use and selection of agents apart from using strict criteria
for IOL should underpin this intervention. It is argued that
IOL can place more strain on birthing suite workload than
spontaneous labour [1]. Therefore, timing of IOL is also of
importance which again is related to the induction delivery
interval.
ItappearsfromthissmallretrospectivestudythatProstin
is more likely to achieve a quicker delivery, regardless of
the mode of delivery, in nulliparous women following IOL
than Cervidil. This was not observed by others [5]w h o
however, used a diﬀerent proprietary long-acting retrievable
preparation.Anearlierlargerbutsimilarretrospectivecohort
study [4] had noted that nulliparous women induced
with the longer acting preparation had signiﬁcantly longer
median insertion to vaginal birth interval. The ﬁnding from
this study is likely to have a favourable impact especially
for elective IOL which is known to aﬀect the workload in
birth suite. The concern amongst women undergoing IOL
about the length of labour is well known [13]. Hence, it
is believed [14] that women are likely to value a reduction
in the interval between induction and delivery. Therefore
the ﬁnding that the preparation which is associated with a
signiﬁcant reduction in the delivery time irrespective of the
mode of delivery being used in their care is likely to go down
favourably with the women undergoing IOL.
Rate of caesarean section in primiparous women, a
VLAD indicator, does not appear to be increased with
either Prostin or Cervidil, and hence there was no impact
on the overall performance. The indications for caesarean
sections in both groups included acute foetal bradycardia
not responding to intrauterine resuscitative measures, foetal
acidaemia determined by foetal scalp lactate and/or pH and
base excess, arrest of labour in the ﬁrst stage despite aug-
mentationwithoxytocins,andfailedassistedvaginaldelivery
apart from failed induction. However, the numbers in each
of these groups were too small to calculate any statistical
signiﬁcance. There was no incidence of hyperstimulation
with either preparation.
This study, however, shows that using Prostin for IOL
is more likely to be associated with assisted vaginal delivery
than Cervidil though the overall incidence of operative
deliveries (assisted vaginal delivery and caesarean section)
is no diﬀerent with the use of either agent. This greater
incidence of assisted vaginal delivery with Prostin compared
to Cervidil was not addressed in a previous study [4]. It
is uncertain whether this greater likelihood of successful
assisted vaginal delivery was due to the fact that the
department had signiﬁcantly more doctors in their advanced
years of training in the second half of the year than in the
ﬁrst. There is good evidence of higher incidence of caesarean
section at full dilatation with lesser experienced operators
[15]. During the study period, there was only one instance of
failed assisted vaginal delivery which resulted in a caesarean
section at full dilatation. Incidentally, most of the caesarean
sections done in the 3 months of Cervidil use were done in
the ﬁrst stage of labour and hence less likely to have been
inﬂuenced by operator skill.
Thisstudyneverthelesshasseverallimitations.Thenum-
bers are small, and the data relates to a single birthing4 The Scientiﬁc World Journal
unit in one hospital. The time frame used in this study
is only six months with three months on either side of
change in practice. The study is not a randomised trial but
retrospective data analysis. It is also diﬃcult to explain why
women having IOL with Prostin achieved an earlier delivery
than those who were induced with Cervidil. The basic
mechanism of action with either preparation is essentially
the same being mediated through a combination of reduced
collagen concentration and dissociation of collagen ﬁbrils
by activation of the collagenase enzyme apart from the
alterations in glycosaminoglycan composition and hydration
[16].Onereasonmaybetheadditiveeﬀectsofrepeateddoses
of Prostin compared to the slow-release Cervidil preparation
that allowed an earlier amniotomy and oxytocin augmenta-
tion. This would have allowed a diagnosis of failed IOL or an
operative delivery earlier. However, these interventions did
not reach any statistical signiﬁcance between the two arms.
5. Conclusion
In conclusion, this is a small study comparing the out-
come of IOL in nulliparous women following a change in
clinical practice after replacement of a long-acting vaginal
prostaglandin E2 by a shorter-acting preparation. IOL with
theshorteractingpreparationwaslikelytoresultinaquicker
delivery regardless of the mode of delivery (operative or
vaginal), a feature likely to be appreciated by the women
undergoing the intervention. This albeit was associated with
a higher assisted vaginal delivery rate, but there was no
signiﬁcant diﬀerence in the caesarean section or overall
(spontaneous and assisted) vaginal delivery rates.
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